Rallybio Ipa, LLC

Prophylix Pharma As

Universitetet I TromsØ—norges Arktiske Universitet

University Hospital of North Norway

Norinnova Technology Transfer As

Tto Nord As

Anne Husebekk

Bjorn Ragnar Skogen

Terje Michaelsen

Heidi Tiller

Mariana Eksteen

Oistein Ihle

Tor Brynjar Stuge

Jens Kjeldsen-Kragh

Mette Kjaer Killie

Mette Kjaer

ØIstein Ihle

Bjørn Ragnar Skogen

Bjørn Skogen

Mette Kjær Killie

Provided is an isolated antibody that specifically binds to HPA-1a. Also provided is a nucleic acid molecule that encodes the antibody, and compositions comprising the antibody. Also provided is a method of producing the antibody and methods and uses which employ the antibody. Also provided are therapeutic uses of the antibody, for example in the treatment or prophylaxis of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

Antibodies against HPA-1a

The present invention provides an isolated antibody that specifically binds to HPA-1a. Also provided is a nucleic acid molecule that encodes the antibody, and compositions comprising the antibody. Also provided is a method of producing the antibody and methods and uses which employ the antibody. Also provided are therapeutic uses of the antibody, for example in the treatment or prophylaxis of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

A preparation useful for, and a method for the prophylactic treatment of women post-childbirth in order to avoid immunization and antibody production, which could induce NAIT and fetal/neonatal bleeding in subsequent pregnancies comprising administering a preparation containing antibodies to HPA 1a within 72 hours after delivery in the first non-compatible pregnancy.

Preparation useful for, and method for treatment of neonatal alloimmune thrombocytopenia (NAIT)

Growing community of inventors

Tromso, Norway

Anne Husebekk